BioCentury
ARTICLE | Clinical News

Latuda: Ph III Illuminate data

March 17, 2017 1:01 PM UTC

Top-line data from the double-blind, international Phase III Illuminate trial in about 471 patients ages 10-17 with depression associated with bipolar I disorder showed that flexible dosing with once-daily 20-80 mg Latuda met the primary endpoint of improving CDRS-R total score from baseline to week 6 vs. placebo. Latuda also met the secondary endpoint of improving CGI-BP-S score for depression from baseline to week 6 vs. placebo...